about
Beyond CA125: the coming of age of ovarian cancer biomarkersAssessing lead time of selected ovarian cancer biomarkers: a nested case-control studyMesothelin promotes cell proliferation in the remodeling of neonatal rat pancreas.Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs.Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.Immunoassays for the cancer biomarker CA125 based on a large-birefringence nematic liquid-crystal mixtureFibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomasClinically relevant microRNAs in ovarian cancerOptimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.MUC16/CA125 in the context of modular proteins with an annotated role in adhesion-related processes: in silico analysis.Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood.Integrated Microfluidic Lectin Barcode Platform for High-Performance Focused Glycomic Profiling.Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survivalImmuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imagingPreclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.Synthesis and pre-clinical evaluation of an (18)F-labeled single-chain antibody fragment for PET imaging of epithelial ovarian cancerExploring the glycosylation of serum CA125.Can CA-125 predict lymph node metastasis in epithelial ovarian cancers in Turkish population?Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis.Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer.Proteome signatures--how are they obtained and what do they teach us?Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.Effect of genetic and environmental factors on protein biomarkers for common non-communicable disease and use of personally normalized plasma protein profiles (PNPPP).Spontaneously Ruptured Paraovarian Tumor of Borderline Malignancy with Extremely Elevated Serum Carbohydrate Antigen 125 (CA125) Levels: A Comparison of the Imaging and Pathological Features.Tumor-derived exosomes in ovarian cancer - liquid biopsies for early detection and real-time monitoring of cancer progression.Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.Selected reaction monitoring approach for validating peptide biomarkers.Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells
P2860
Q24651567-79E244C8-2540-456E-BA39-41393D9223EAQ33574039-65BCD63E-ECC5-4237-B6E4-57A6490A8351Q33735285-C0CA417A-BF0C-4C3D-A00D-1327095F69A3Q34086395-8188294A-25AC-4EC6-A21D-12080E92D62CQ34675023-C0A42546-531F-4B1D-9573-E28104B065C6Q35049258-641A6CB8-5CD8-4450-9131-D697F1A8746DQ35177014-39BBFBB6-3CA5-4CBC-AA5F-44318B166735Q35204609-9AE5D7C5-0089-43C4-B2B4-32827D9BB782Q35837949-A174E283-C511-439C-9550-34876DA30087Q36202486-6B4AA302-2E6F-45AB-9813-EE0698102C15Q36250701-4519F3E2-2149-45DC-AECC-853A4A0BA0E1Q36528533-DFC1A510-46CC-4CB7-A777-C3063F560CD9Q36546798-F82AF1C6-FA23-47AE-8204-EEAC7A696B92Q36944360-2BE51ADA-2132-45C0-B0E2-8C61167E9DA6Q37122878-0232B4B1-F121-4348-B7D3-93768759E873Q37136748-667CC951-E73A-4D48-84E8-FB28A14C9764Q37139074-9C756F4A-CB92-4D3F-979D-88C110C08AE9Q37699931-2280ECCC-7DAF-4DAE-896D-B51E5332DE93Q37730676-50F6AC2B-CE96-4730-BA72-B212FC9FDC73Q37873930-394C56A9-6625-42FF-B86C-C53C7C9BFF8EQ38553042-052ABB55-C8BD-4A0B-8FEE-D4378AF0B6C1Q38957886-7E55D5D1-81FC-4ACF-8A91-14B7B9ECDDA3Q40340848-28B20182-08DA-4036-8575-068AC7255CB7Q41589688-B9B51163-D6C5-487D-8E4D-F164AEF4FB73Q47134018-C7F44CD2-5E3D-49B5-82E4-B0254D3F7404Q47221063-352D1693-346F-4E71-80D6-0A1175AEC643Q47285459-E6BF4F33-0F49-4205-8631-1E8074E55930Q55297626-3EBEE028-EE76-42F9-9E55-735DABFE4B75Q58609457-96464889-51FD-4306-B869-A7AF67C0D51C
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
CA125 in ovarian cancer
@ast
CA125 in ovarian cancer
@en
type
label
CA125 in ovarian cancer
@ast
CA125 in ovarian cancer
@en
prefLabel
CA125 in ovarian cancer
@ast
CA125 in ovarian cancer
@en
P2860
P356
P1476
CA125 in ovarian cancer
@en
P2093
Nathalie Scholler
Nicole Urban
P2860
P304
P356
10.2217/17520363.1.4.513
P577
2007-12-01T00:00:00Z